Research programme: mitogen activated protein kinase inhibitors - Kura Oncology

Drug Profile

Research programme: mitogen activated protein kinase inhibitors - Kura Oncology

Alternative Names: KO 947

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Arexis
  • Developer Kura Oncology
  • Class Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 04 Jan 2017 US FDA approves IND application for KO 947 in Solid tumours
  • 01 Dec 2016 Pharmacodynamics data from preclinical trials in Solid tumours presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC 2016)
  • 17 Mar 2016 Kura Oncology announces intention to submit IND to US FDA in the second quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top